Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 Biomarker disease BEFREE Therapeutic targets of interest include mutated molecules that predispose to pancreatic cancer such as KRAS and TP53. 23436799 2013
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 Biomarker disease BEFREE Dietary Garcinol Arrests Pancreatic Cancer in p53 and K-ras Conditional Mutant Mouse Model. 30273070 2018
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 GeneticVariation disease BEFREE Our results demonstrate that p53 mutation is an early genetic event affecting a diversity of molecular pathways in pancreatic carcinogenesis and indicates a possibility of early diagnosis of pancreatic carcinoma by detecting a few p53-positive cells obtained from the pancreatic fluid. 19248224 2009
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 AlteredExpression disease BEFREE Taken together, our data indicate that PRIMA-1 induces apoptosis in p53 mutant pancreatic cancer cells by promoting the re-activation of p53 and inducing proapoptotic signaling pathways, providing in vitro evidence for a potential therapeutic approach in pancreatic cancer. 24838627 2014
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 Biomarker disease BEFREE The clinicopathologic implications of p53 abnormalities and their effects on the efficacy of the adjuvant chemotherapy for pancreatic cancer remain controversial. 12561067 2003
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 GeneticVariation disease BEFREE This study confirms that loss of chromosomes, particularly chromosomes 17 and 18, which carry the p53 and DCC genes, are common in pancreas cancer.Chromosome 20 is also frequently lost. 10090407 1999
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 Biomarker disease BEFREE In this study, we investigated the relationship between SRPK2, Numb and p53 in the development of pancreatic cancer with or without chemical agent treatment in vitro. 30724469 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 GeneticVariation disease BEFREE Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer. 28121262 2017
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 GeneticVariation disease BEFREE Potential functional variants in SMC2 and TP53 in the AURORA pathway genes and risk of pancreatic cancer. 30794721 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 GeneticVariation disease BEFREE Therefore, simultaneous analysis of p53 and K-ras mutation is suggested to enhance the genetic diagnosis of pancreatic cancer. 10353750 1999
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 GeneticVariation disease BEFREE The concomitant expression of oncogenic Kras(G12D) and mutant p53 (Trp53(R172H)) in the murine pancreas results in metastatic PDA that recapitulates the cognate features of human pancreatic cancer providing an excellent animal model to identify genes required for tumor progression. 22158044 2012
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 GeneticVariation disease BEFREE Advances in the understanding of pancreas cancer biology have been made over the past decade, including the discovery of critical mutations in oncogenes (i.e., K-Ras) as well as the loss of tumor suppressor genes, such as TP53 and p16(INK4). 16818496 2006
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 Biomarker disease BEFREE Hypoxia-induced feedback of HIF-1α and lncRNA-CF129 contributes to pancreatic cancer progression through stabilization of p53 protein. 31367258 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 AlteredExpression disease BEFREE Pancreatic cancer is particularly resistant to apoptosis by antineoplastic agents, which is partly attributable to the lack of functional p53. 11585734 2001
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 GeneticVariation disease BEFREE In pancreatic cancer mutations in oncogenes and tumor suppressor genes are frequently detected in p53 and K-ras. 8862512 1996
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 GeneticVariation disease BEFREE Although the rate of p53 mutations in pancreatic tumours is of the same order as in other adenocarcinomas (> or = 50%), an antibody response was found in only 5/78 (6.4%) sera from patients with pancreatic cancer. 7947080 1994
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 PosttranslationalModification disease BEFREE Enhanced phosphorylation of p53 by microRNA-26a leading to growth inhibition of pancreatic cancer. 26189069 2015
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 GeneticVariation disease BEFREE Overexpression of Gli1, MDM2 and mutant p53 contributes to the development and progression of PC, and plays an important role in predicting PC patients' prognosis. 24289472 2014
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 GeneticVariation disease BEFREE Together, this study highlights the therapeutic potential of NL in mutant p53 expressing pancreatic cancer. 29107110 2018
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 GeneticVariation disease BEFREE Moreover, p53 mutations were detected in 7 of 15 (46.7%) cases of PCa in which the cytologic diagnosis was negative. 14707724 2004
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 GeneticVariation disease BEFREE Eight out of 30 tissues from primary pancreas cancer and 3 of 4 samples from metastases showed p53 mutations. 8026879 1994
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 Biomarker disease BEFREE RESULTS The most important biotargets for plumbagin in PC were identified as TP53, MAPK1, BCL2, and IL6. 31230062 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 Biomarker disease BEFREE Thus, we investigate the relationship among MSI2, Numb, MDM2, and p53 in PC <i>in vitro</i> and <i>in</i><i>vivo</i>, an association that has not been reported to our knowledge. 28223335 2017
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 Biomarker disease BEFREE Concurrent loss of p53 and K-ras function may contribute to the clinical aggressiveness of pancreas cancer. 9219065 1997
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 Biomarker disease BEFREE Adenovirus-mediated p53 gene transfer suppressed growth of all human pancreatic cancer cell lines in a dose-dependent manner. 9869513 1998